Orthocell Limited
ASX: OCC
Growth trajectory strengthening, but market pricing still reflects hesitation and incomplete re-rating.
(Source: TradingView) 3-Month Performance Profile of OCC on a DTF compared to S&P/ASX 200 (XJO).
OCC reported a strong 1H FY26 performance, with revenue rising 48% to around $6.2 million, driven by growing global adoption of its Remplir nerve repair p
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
